Content area
Abstract
(CCNMatthews - Aug. 9, 2006) - ViRexx Medical Corp. (TSX:VIR) (AMEX:REX) a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumors, announced today that enrolment and treatment has been completed in the Phase I trial for HepaVaxx B Vaccine, the lead candidate from ViRexx's novel Chimigen(TM) vaccine platform. The trial has enrolled and vaccinated its target of 15 healthy volunteers with a subcutaneous injection of HepaVaxx B Vaccine. There were no significant adverse events associated with the treatment.